OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	86
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	38
Monoclonal Gammopathy-Associated Neuropathy	28
Management of Chronic Myeloid Leukemia in Children and Young Adults	24
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	22
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	18
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	17
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	17
Value in Myeloma Care: Myth or Reality	14
Treatment-Free Remission: the New Goal in CML Therapy	14
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	14
Challenges in Chronic Myeloid Leukemia Management in South America	13
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses	12
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	12
Targeting Apoptosis in ALL	12
Prognostic and Predictive Models in Myelofibrosis	11
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic	11
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies	10
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift	10
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	10
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	10
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	9
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions	9
How Do We Manage Chronic Lymphocytic Leukemia in India	9
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)	9

Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	8
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	8
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	8
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	7
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	7
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	7
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	7
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center	7
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	7
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	6
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	6
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia	6
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	6
Avapritinib in the Treatment of Systemic Mastocytosis: an Update	6
Myeloproliferative Neoplasms with Monocytosis	6
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	6
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	6
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	5
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	5
Pediatric Germline Predisposition to Myeloid Neoplasms	5
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	5
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	5
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	5
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	5
Real-world Management of CML: Outcomes and Treatment Patterns	4
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	4
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk	4
Measurable Residual Disease Monitoring in Lymphoma	4
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera	4
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	4
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia	4
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	3
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments	3
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management	3
Managing Survivorship after Hematopoietic Cell Transplantation	3
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	3
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	3
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	3